NASDAQ:ANABAnaptysBio Stock Price, Forecast & News

AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ANAB shares have increased by 30.5% and is now trading at $19.87. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AnaptysBio.

AnaptysBio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for AnaptysBio.

AnaptysBio Inc (NASDAQ:ANAB) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.33. The biotechnology company had revenue of $15 million for the quarter, compared to analysts' expectations of $10 million. View AnaptysBio's earnings history.

9 brokers have issued twelve-month price objectives for AnaptysBio's shares. Their forecasts range from $12.00 to $140.00. On average, they anticipate AnaptysBio's share price to reach $48.86 in the next year. This suggests a possible upside of 145.9% from the stock's current price. View analysts' price targets for AnaptysBio.

News articles about ANAB stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AnaptysBio earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutAnaptysBio.

Some companies that are related to AnaptysBio include Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), SAGE Therapeutics (SAGE), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Pacira Biosciences (PCRX), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH), Corcept Therapeutics (CORT), Xencor (XNCR), IGM Biosciences (IGMS), Arvinas (ARVN), Zogenix (ZGNX) and Eidos Therapeutics (EIDX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Crispr Therapeutics (CRSP), ImmunoGen (IMGN), Editas Medicine (EDIT), NVIDIA (NVDA), Amarin (AMRN), Alibaba Group (BABA), bluebird bio (BLUE), Baozun (BZUN), Canopy Growth (CGC) and Clovis Oncology (CLVS).

(ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (8.40%), BlackRock Inc. (7.44%), State Street Corp (7.17%), Federated Hermes Inc. (4.67%), Cormorant Asset Management LP (4.06%) and Morgan Stanley (1.85%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria and Marco Londei. View institutional ownership trends for AnaptysBio.

ANAB stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Morgan Stanley, Morgan Stanley, Perceptive Advisors LLC, Perceptive Advisors LLC, Prosight Management LP, JPMorgan Chase & Co., and Alliancebernstein L.P.. Company insiders that have sold AnaptysBio company stock in the last year include Hamza Suria, and Marco Londei. View insider buying and selling activity for AnaptysBio.

ANAB stock was acquired by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Tang Capital Management LLC, Rock Springs Capital Management LP, Two Sigma Advisers LP, Thrivent Financial for Lutherans, Voloridge Investment Management LLC, AXA, and State Board of Administration of Florida Retirement System. View insider buying and selling activity for AnaptysBio.

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ANAB stock can currently be purchased for approximately $19.87.

AnaptysBio has a market capitalization of $541.99 million and generates $8 million in revenue each year. The biotechnology company earns $-97,340,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. AnaptysBio employs 78 workers across the globe.

The official website for AnaptysBio is www.anaptysbio.com.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]